Pfizer Biologics (Hangzhou) Co., Ltd was established in November 2015. With registered capital of $115 million, it is a wholly foreign-owned enterprise invested and established by Pfizer and is located in Hangzhou Economic and Technology Development Zone. The project is Pfizer’s largest overseas investment project of the past decade, the third biotechnology center in the world after the United States and Ireland, and the first R&D and production base of monoclonal antibodies set up by one of the world’s top 500 multinational companies in China.

With an investment of $350 million, the first phase of the project covers an area of 56,013 square meters. The company is expected to employ 150 staff and introduce several new biosimilar medical products. 

The center adopts the most advanced modular production facilities in the world, disposable production technology, and a complete isolator production system to ensure maximum product quality. Meanwhile the center is cultivating a group of advanced local talents with biotechnology knowledge who will help to promote indigenous innovation and the modernization of China’s biopharmaceutical industry. 

The Pfizer Global Biotechnology Center is the first macromolecular biotechnology innovation project introduced into Zhejiang province and will play a leading role in the rapid development of the biomedical industry. The completion of the project will lead to the localized production of world-class, highly-efficient and safe biological agents in China, enhance the reputation of China’s manufacturing industry all over the world, help to promote “Made in China 2025” program and export of high-valued products, and enhance China’s position in the field of international pharmaceutical development.